IDH-Based Therapeutics for the Treatment of Glioma

IDH1 mutations are presumed to drive the formation of lower-grade glioma and as such may directly or indirectly serve as a therapeutic target.  We are interested in determining the dependence of lower-grade glioma on IDH1 mutation and in developing ways to use IDH1 mutation and its consequences as targets and biomarkers of therapeutic intervention. 

We have shown that although IDH1 mutations can drive gliomagenesis, they do not appear to be required for continued tumorigenicity.  We are therefore interested in determining how other agents can be used alone or in combination with IDH1 inhibitors to target the pathways relied upon by mutant IDH1-driven tumors.

Related Publications

Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, Pieper RO. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. Mol Cancer Res. 2016 Oct;14(10):976-983. Epub 2016 Jul 18.

Viswanath P, Najac C, Izquierdo-Garcia JL, Pankov  A, Hong C, Eriksson P, Costello JF, Pieper RO, Ronen SM. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Oncotarget. 2016 Jun 7;7(23):34942-55.